Crocchiolo Roberto, Alfarano Francesco, Volpato Elisabetta, Pugliano Mariateresa, Cuppari Irene, Mazza Anna Maria, Bellio Laura, Fanti Diana, Vismara Chiara, Scaglione Francesco, Sacchi Nicoletta, Pollichieni Simona, Mele Lia, Diral Elisa, Grillo Giovanni, Rossini Silvano
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):13-16. doi: 10.1016/j.htct.2021.09.017. Epub 2021 Dec 7.
Soon after the onset of the SARS-CoV-2 pandemic, viral screening by nasopharyngeal swab became mandatory for allogeneic hematopoietic stem cell (HSC) donor eligibility.
We described our monocenter experience with allogeneic HSC donors from February 1 to the October 31, 2020 to verify whether the introduction of SARS-CoV-2 screening altered the donor eligibility and/or entailed a prolongation of the evaluation process.
A total of 21 allogeneic HSC donors were screened during the above-mentioned period upon request by the local transplant physicians or by the Italian Bone Marrow Donor Registry; among the HSC donors ( = 17) who completed the eligibility process and further received the nasopharyngeal swab, all but one were negative for the presence of SARS-CoV-2. The positive donor remained asymptomatic for the whole duration of the infection, which lasted six weeks. However, he was temporarily excluded from donation. The median duration of the evaluation process was not significantly different, compared to the same period of 2019 (-value = 0.11).
The mandatory SARS-CoV-2 screening in allogeneic HSC donors allowed for the detection of 6% positivity in this monocenter series over a 9-month period. Despite the inconvenience of this unexpected non-eligibility, the exclusion of a SARS-CoV-2 positive donor represented an important safety measure for the donor, with respect to a new and still partially unknown virus. The screening did not alter the length of the donor evaluation and thus, did not cause a delay in the eligibility process.
在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行开始后不久，对异基因造血干细胞（HSC）供体资格进行鼻咽拭子病毒筛查成为强制性要求。
我们描述了2020年2月1日至10月31日期间我们在异基因HSC供体方面的单中心经验，以验证SARS-CoV-2筛查的引入是否改变了供体资格和/或是否导致评估过程延长。
在上述期间，应当地移植医生或意大利骨髓捐献者登记处的要求，共对21名异基因HSC供体进行了筛查；在完成资格审核并进一步接受鼻咽拭子检测的HSC供体（n = 17）中，除1人外，所有供体的SARS-CoV-2检测均为阴性。阳性供体在整个感染期间（持续六周）均无症状。然而，他被暂时排除在捐献之外。与2019年同期相比，评估过程的中位持续时间无显著差异（P值 = 0.11）。
对异基因HSC供体进行强制性SARS-CoV-2筛查，在这个单中心系列中，9个月内检测到6%的阳性率。尽管这种意外的不符合资格带来了不便，但对于一种新的且仍部分未知的病毒而言，排除SARS-CoV-2阳性供体对供体来说是一项重要的安全措施。筛查并未改变供体评估的时长，因此，也未导致资格审核过程的延迟。
